Good day, ladies and gentlemen, thank you for standing by. Welcome to the Patterson Companies Fourth Quarter Fiscal 2014 Earnings Announcement Conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be opened for ...
Kiadis Pharma’s Pediatric Investigation Plan for ATIR101™ accepted by the European Medicines Agency’s Pediatric Committee
We've upgraded our moat ratings for Henry Schein and Patterson Companies to wide on distribution network cost advantages and high switching costs among their fragmented customers and suppliers.
Market volatility has shaped the performance of many top managers this year.
Distributors Henry Schein and Patterson should be able to maintain their competitive advantages over the long run and deserve a spot on investors' watchlists.